FDA Approves SCOPOLAMINE — Mylan Pharmaceuticals Inc.

Mylan received FDA approval on June 19, 2019, for the generic transdermal formulation of scopolamine, signaling a significant opportunity for market expansion into the motion-sickness sector. This approval for ANDA203753 is expected to provide intense competitive pressure on brand competitors by offering more affordable access to this chronic OTC treatment.